Alemtuzumab - CISMeF

Preferred Label : Alemtuzumab;

NCIt related terms : Campath-1H;

NCIt definition : A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04);

Alternative definition : NCI-GLOSS: A type of monoclonal antibody used in the treatment of leukemia. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.;

UNII : 3A189DH42V;

CAS number : 216503-57-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 216503-57-0 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : MabCampath; Campath; Lemtrada; Campath-1H;

Molecule name : LDP-03;

NSC code : 715969;

Codes from synonyms : CDR0000044002; CDR0000044851; 17;

Details

Origin ID

C1681;

UMLS CUI

C0383429;

Automatic exact mappings (from CISMeF team)
- Alemtuzumab [ICD-11 Extension code]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Alemtuzumab [MeSH Descriptor]
- Alemtuzumab (substance) [SNOMED CT concept]
- Product containing alemtuzumab (medicinal product) [SNOMED CT concept]
- alemtuzumab [ATC Code]
- alemtuzumab [International Nonproprietary Name]
- alemtuzumab [MeSH concept]
Validated automatic mappings to BTNT
- alemtuzumab [ATC Code]
chemical_or_drug_affects_gene_product
- CAMPATH-1 Antigen [NCIt concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
chemical_or_drug_has_physiologic_effect
- Antibody-Dependent Cellular Cytotoxicity [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- HemOnc Agent Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- CAMPATH-1 Antigen [NCIt concept]
is_component_of_chemotherapy_regimen
- Alemtuzumab Regimen [NCIt concept]
- Alemtuzumab/Cyclophosphamide/Doxorubicin/Etoposide/Prednisone/Vincristine [NCIt concept]
- Alemtuzumab/Cyclophosphamide/Fludarabine [NCIt concept]
- Alemtuzumab/Fludarabine [NCIt concept]
- Alemtuzumab/Fludarabine/Melphalan [NCIt concept]
- Alemtuzumab/Pentostatin Regimen [NCIt concept]
- Alemtuzumab/Rituximab Regimen [NCIt concept]
- CFAR Regimen [NCIt concept]
- FMC/Alemtuzumab Regimen [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients